Thalidomide Suppressed IL-1β While Enhancing TNF-α and IL-10, When Cells in Whole Blood were Stimulated with Lipopolysaccharide

REFERENCES

• J. Sheskin. (1965). Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6:303–306.
   PubMed Web of Science ®Google Scholar
• R. Hasting, J. Trautman, C. Enna, and R. Jacobson. (1970). Thalidomide in the treatment of erythema nososum leprosum, with a note on selected laboratory abnormalities in erythema nodosum leprosum. Clin. Pharmacol. Ther. 11:481–487.
   PubMedGoogle Scholar
• K. Zwingenberger, and S. Wendt. (1996). Immunomodulation by thalidomide: Systematic review of the literature and on unpublished observations. J. Inflamm. 46:177–211.
   Google Scholar
• E. Sampaio, E. Sarno, R. Galilly, Z. Cohn, and G. Kaplan. (1993). Thalidomide selectively inhibits TNF-α production by stimulated human monocytes. J. Exp. Med. 173:699–703.
   Google Scholar
• E. Sampaio, G. Kaplan, A. Miranda, C. Nery, S Miguel, G. Nery, C. Miguel, S. Vianas, and E. Sarno. (1993). The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168:408–414.
   PubMed Web of Science ®Google Scholar
• J. Baraniuk. (1966). Steroids in asthma: molecular mechanisms of glucocorticoid actions. J. Allergy Clin. Immunol. 97:141–177.
   Google Scholar
• E. Shannon, and F. Sandoval. (1996). Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol. Immunotoxicol. 18 (1):59–72.
   PubMedGoogle Scholar
• L. Corral, P. Haslett, G. Muller, R. Chen, Wong Lu-Min, C Ocampo, R. Patterson, D. Stirling, and G. Kaplan. (1999). Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α.. J. Immunol. 163:380–386.
   PubMed Web of Science ®Google Scholar
• P. Haslett, J. Klausner, L. Corral, M. Albert, and G. Kaplan. (1998). Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187:1885–1892.
   PubMed Web of Science ®Google Scholar
• D. DeGroote, P. Zangerle, Y. Gevaret, M. Fassotte, Y. Beguin, and F. Noizat-Pirenne. (1992). Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IFN-γ and GM-CSR) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine. 4 (3):239–248.
   PubMedGoogle Scholar
• IL Elenkov, D.A. Papanicolaoua, R.L. Wilder, and G.P. Chrousos. (1996). Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: Clinical Implications. Proc. Assoc. Am. Physicians. 108 (5):374–381.
   PubMedGoogle Scholar
• J. Visser, A. Van Boxel-Dezaire, D. Methorst, T. Brunt, E. de Kloet, and L. Nagelkerken. (1998). Differential Regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vivo.. Blood. 91 (11):4255–4264.
   PubMedGoogle Scholar
• E. Shannon, F. Sandoval, and J. Krahenbuhl. (1997). Hydrolysis of thalidomide abrogates its ability to enhance the synthesis of IL-2 and suppress the synthesis of TNF-α.. Immunopharm. 36:5–19.
   Google Scholar
• L. Corral, G. Muller, A. Moreira, Y. Chen, M. Wu, D. Stirling, and G. Kaplan. (1996). Selection of novel analogs to thalidomide with enhanced tumor necrosis factor inhibitory activity. Mol. Med. 2:506–515.
   PubMed Web of Science ®Google Scholar
• A. Tadesse, and E. J. Shannon. (2005). Concerns regarding In Vitro and In Vivo Uses of Thalidomide. Letter to the Editor, Lepr. Rev. 76 (1):94–9.
   PubMedGoogle Scholar
• T. Eriksso. Pharmacokinetics of the enantiomers of thalidomide. Ph.D. dissertation. Department of Clinical Pharmacology, Lund University, Lund, Sweden, (1997).
   Google Scholar
• S. Hodge, G. Hodge, R. Flower, and P. Han. (1999). Methyl-prednisolone up-regulates monocyte interleukin-10 production in stimulated whole blood. Scand. J. Immunol. 49:548–553.
   PubMed Web of Science ®Google Scholar
• P. Sreenivasan, R. Misra, D. Wilfred, and I. Nath. (199). Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type1 and 2 reactions. Immunology. 95:529–536.
   PubMedGoogle Scholar
• M. Moraes, E. Sarno, M. Rosane, E. Teles, R. Teles, A. Almedia, B. Saraiva, J. Nery, and E. Sampaio. (2000). Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J. Invest. Dermatol. 115 (6):935–941.
   PubMedGoogle Scholar
• M. Adob-Conquy, Anne-France Petit, M. Christelle, and C. Fitting. (1999). Paradoxical priming effects on IL-10 on cytokine production. Int. Immunol. 11 (5):689–698.
   PubMedGoogle Scholar
• S. Makanokaweyoon, R. Limson-Probe, A. Moreia, V. Schauf, and G. Kaplan. (1993). Thalidomide inhibits the replication of human immunodeficiency virus type I.. Proc. Natl. Acad. Sci. U. S. A. 90:5974–5978.
   PubMed Web of Science ®Google Scholar
• J. Marriott, I. Clarke, K. Dredge, G. Muller, D. Stirling, and A. Dalgleish. (2002). Thalidomide and its analogues have distinct and opposing effects on TNF-α during stimulation of both CD4+ and CD8+ T-cells. Clin. Exp. Immunol. 130:75–84.
   PubMed Web of Science ®Google Scholar
• E. Shannon, and F. Sandoval. (1995). Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 31:109–116.
   PubMed Web of Science ®Google Scholar
• E. Shannon, and F. Sandoval. (2002). Thalidomide can suppress or enhance CD4+ cells ability to incorporate [H3]-thymidine-a dependency on the stimulant. Int. Immunopharmacology. 2:1143–1153.
   PubMed Web of Science ®Google Scholar
• E. Shannon, R. Noveck, F. Sandoval, B. Kamath, and M. Kearney. (2007). Thalidomide suppressed IL-6 but not TNF-alpha in volunteers with experimental endotoxemia. Translational Research. 150 (5):275–280.
   PubMedGoogle Scholar
• L. Villahermosa, T. Tranquilino, J. Fajardo, R. Abalos, M. V. Balagona, and E. A. Tan. (2005). randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am. J. Trop. Med. Hyg. 72 (5):518–526.
   PubMedGoogle Scholar
• R. Teles, M. Moraes, and T. Natasha. (2002). Differential TNF-α regulation detected in the epidermis of leprosy patients. Arch. Dermatol. Res. 294:355–362.
   PubMedGoogle Scholar
• P. Haslett, P. Roche, C. Butlin, M. Macdonald, N. Shrestha, R. Manandhar, J. Lemaster, R. Hawksworth, M. Shah, A. Lubinsky, A. Albert, J. Worley, and G. Kaplan. (2005). Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J. Infect. Dis. 192:2045–2053.
   PubMed Web of Science ®Google Scholar
• A. Tadesse, M. Abebe, E. M. Bizuneh, A. Aseffa, and E. Shannon. (2006). The effect of thalidomide on the expression of TNF-α mRNA and the synthesis of TNF-α in cells from leprosy patients with reversal reaction. Immunopharmacol. Immunotoxicol. 28 (3):431–441.
   PubMedGoogle Scholar
• A. Tadesse, and E. Shannon. (2005). Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages. Clin. Diag. Lab. Immunol. 12 (1):130–134.
   PubMedGoogle Scholar
• S. Khanolkar-Young, N Rayment, P. M. Brickell, D. Katz, S. Vinayakumar, M. Colson, and D. Lockwood. (1995). Tumour necrosis factor-alpha (TNF-α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin. Exp. Immunol. 9:196–202.
   Google Scholar
• M. R. Shalaby, M. A. Palladino, S. E. Hirabayashi, T. E. Eessalu, G. D. Lewis, H. M. Shepard, and B. Aggarwal. (1987). Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J. Leuko. Biol. 41:196–204.
   PubMed Web of Science ®Google Scholar
• Y. Otsuka, K. Nagano, K. Nagano, K. Hori, Oh-Ishi, Jun-ichi, and H. Hauashi. (1999). Inhibition of neutrophil migration by tumor necrosis factor: ex vivo and in vivo studies in comparison with in vitro effects. J. Immunol. 145 (8):2639–2643.
   Google Scholar
• B. Tavares-Murta, and F. Cunha. (1998). The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide. Br. J. Pharmacol. 124:1369–1374.
   PubMedGoogle Scholar
• A. Moreira, and G. Kaplan. (1998). Comparison of pentoxfylline, thalidomide and prednisone in the treatment of ENL. Letter to the Editor. Int. J. Leprosy. 66 (1):61–64.
   Google Scholar